1.Primary structure of mature SAG1 gene of an Indonesian Toxoplasma gondii and comparison with other strains.
Sri HARTATI ; Asmarani KUSUMAWATI ; Hastari WURYASTUTI ; J Sri WIDADA
Journal of Veterinary Science 2006;7(3):263-270
Toxoplasma gondii is a persistent protozoan parasite capable of infecting almost any warm-blooded vertebrates. SAG1 (p30) is the prototypic member of a superfamily of surface antigens called SRS (SAG1-related sequence). It constitutes the most abundant and predominant antigen. In this paper the primary structure of mature SAG1 gene of an Indonesian T. gondii isolate is described and sequence comparison is made with published sequence data of 7 other strains or isolates. Sequence comparison indicated that SAG1 is highly conserved through evolution and despite parasite spreading world-wide. Sequences may be divided into two major families, independent of the strain/isolate geographic origin. Variations were mainly localized at the C-terminal half or domain 2 and some clustered in restricted areas. Sequence comparison allowed us to define the Indonesian isolate as genuine virulent RH strain. A phylogenetic tree of Toxoplasma strains/isolates was constructed based on SAG1.
Amino Acid Sequence
;
Animals
;
Antigens, Protozoan/chemistry/*genetics
;
Base Sequence
;
Cloning, Molecular
;
DNA, Protozoan/chemistry/genetics
;
Goat Diseases/parasitology
;
Goats
;
Indonesia
;
Molecular Sequence Data
;
Phylogeny
;
Polymerase Chain Reaction
;
Protozoan Proteins/chemistry/*genetics
;
Sequence Alignment
;
Sequence Analysis, DNA
;
Toxoplasma/*genetics/*immunology/isolation&purification
;
Toxoplasmosis/parasitology
;
Zoonoses/parasitology
2.Potential of polylactic-co-glycolic acid (PLGA) for delivery Jembrana disease DNA vaccine Model (pEGFP-C1-tat)
Lalu UNSUNNIDHAL ; Raden WASITO ; Erif Maha NUGRAHA SETYAWAN ; Ziana WARSANI ; Asmarani KUSUMAWATI
Journal of Veterinary Science 2021;22(6):e76-
Background:
The development of a vaccine for Jembrana disease is needed to prevent losses in Indonesia's Bali cattle industry. A DNA vaccine model (pEGFP-C1-tat) that requires a functional delivery system will be developed. Polylactic-co-glycolic acid (PLGA) may have potential as a delivery system for the vaccine model.
Objectives:
This study aims to evaluate the in vitro potential of PLGA as a delivery system for pEGFP-C1-tat.
Methods:
Consensus and codon optimization for the tat gene was completed using a bioinformatic method, and the product was inserted into a pEGFP-C1 vector. Cloning of the pEGFP-C1-tat was successfully performed, and polymerase chain reaction (PCR) and restriction analysis confirmed DNA isolation. PLGA-pEGFP-C1-tat solutions were prepared for encapsulated formulation testing, physicochemical characterization, stability testing with DNase I, and cytotoxicity testing. The PLGA-pEGFP-C1-tat solutions were transfected in HeLa cells, and gene expression was observed by fluorescent microscopy and real-time PCR.
Results:
The successful acquisition of transformant bacteria was confirmed by PCR. The PLGA:DNA:polyvinyl alcohol ratio formulation with optimal encapsulation was 4%:0.5%:2%, physicochemical characterization of PLGA revealed a polydispersity index value of 0.246, a particle size of 925 nm, and a zeta potential value of −2.31 mV. PLGA succeeded in protecting pEGFP-C1-tat from enzymatic degradation, and the percentage viability from the cytotoxicity test of PLGA-pEGFP-C1-tat was 98.03%. The PLGA-pEGFP-C1-tat demonstrated luminescence of the EGFP-tat fusion protein and mRNA transcription was detected.
Conclusions
PLGA has good potential as a delivery system for pEGFP-C1-tat.